Viewing data from:

CARISOPRODOL

ANDA

CARISOPRODOL | A040124 | HIKMA INTERNATIONAL PHARMACEUTICALS LLC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Carisoprodol (2023)

Total Spending

$5.4M

Total Claims

352,126

Beneficiaries

62,766

Avg Cost/Unit

$0.20

Spending Trend

$5.3M(2019)→$5.4M(2020)→$5.7M(2021)→$6.1M(2022)→$5.4M(2023)

YoY Change:-5.2%

5yr CAGR:+0.9%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain7 active DMFs10 inactive

7 active API suppliers hold Drug Master Files for this ingredient.

OLON SPACARISOPRODOL

DMF 44161982

SIEGFRIED EVIONNAZ SACARISOPRODOL

DMF 52401984

UQUIFA ITALIA SPACARISOPRODOL USP

DMF 174442004

APITORIA PHARMA PRIVATE LTDCARISOPRODOL USP

DMF 193882006

HARMAN FINOCHEM LTDCARISOPRODOL USP

DMF 210642007

SOLARA ACTIVE PHARMA SCIENCES LTDCARISOPRODOL USP

DMF 231002009

CHEMECA DRUGS PRIVATE LTDCARISOPRODOL USP

DMF 351492020

WARD BLENKINSOP AND CO LTDInactiveCARISOPRODOL

DMF 51811983

CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTDInactiveCARISOPRODOL

DMF 174002004

SUN PHARMACEUTICAL INDUSTRIES LTDInactiveCARISOPRODOL USP (ACTIVE SUBSTANCE)

DMF 191612006

ISOCHEM SASInactiveCARISOPRODOL

DMF 194082006

FLEMING LABORATORIES LTDInactiveCARISOPRODOL USP

DMF 198012006

ZHEJIANG CHARIOTEER PHARMACEUTICAL CO LTDInactiveCARISOPRODOL USP

DMF 199192006

ALP PHARM BEIJING CO LTDInactiveCARISOPRODOL (DRUG SUBSTANCE, NON-STERILE)

DMF 221182008

UQUIFA MEXICO SA DE CVInactiveCARISOPRODOL

DMF 245462011

POLYDRUG LABORATORIES PVT LTDInactiveCARISOPRODOL

DMF 256872012

FLEMING LABORATORIES LTDInactiveCARISOPRODOL USP

DMF 319652017

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jan 9, 2008	SUPPL -14	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 350MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jan 24, 1996

No patent or exclusivity listings for this strength.